YS Biopharma Co., Ltd. (NASDAQ:YS – Free Report) – Equities researchers at Diamond Equity decreased their FY2024 earnings per share estimates for shares of YS Biopharma in a research note issued to investors on Monday, April 22nd. Diamond Equity analyst H. Diamond now anticipates that the company will post earnings per share of ($0.45) for the year, down from their previous estimate of ($0.24). The consensus estimate for YS Biopharma’s current full-year earnings is ($0.24) per share. Diamond Equity also issued estimates for YS Biopharma’s Q4 2024 earnings at ($0.08) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.02) EPS and FY2025 earnings at ($0.25) EPS.
YS Biopharma (NASDAQ:YS – Get Free Report) last issued its quarterly earnings data on Monday, January 22nd. The company reported ($0.16) EPS for the quarter. The business had revenue of $13.64 million during the quarter.
YS Biopharma Stock Performance
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in YS Biopharma stock. Superstring Capital Management LP purchased a new position in YS Biopharma Co., Ltd. (NASDAQ:YS – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 307,920 shares of the company’s stock, valued at approximately $166,000. Superstring Capital Management LP owned approximately 0.33% of YS Biopharma as of its most recent filing with the Securities & Exchange Commission. 52.64% of the stock is currently owned by institutional investors.
About YS Biopharma
YS Biopharma Co, Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001.
Featured Articles
- Five stocks we like better than YS Biopharma
- Learn Technical Analysis Skills to Master the Stock Market
- Nucor Stock Earnings Riding the Steel Industry Wave
- What is the Dogs of the Dow Strategy? Overview and Examples
- Simpson Manufacturing: Buy This Future Dividend King While Down
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Is Boeing Stock About to Soar Higher?
Receive News & Ratings for YS Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for YS Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.